Ran Reshef

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Heme malignancies and BMT service, Hospital of the University of Pennsylvania
Member, Hematologic Malignancies Research Program, Abramson Cancer Center
Department: Medicine

Contact information
Hospital of the University of Pennsylvania
Division of Hematology & Oncology
Perelman Center for Advanced Medicine, 2nd floor West
3400 Civic Center Blvd.
Philadelphia, PA 19104
Office: 2153498940
Fax: 2156155887
Lab: 2155730642
Education:
B.Med.Sci. (Medical Science)
Tel-Aviv University, Israel, 1996.
M.D. (Medicine)
Sackler School of Medicine at Tel-Aviv University, Israel, 2003.
M.Sc. (Translational Research)
University of Pennsylvania, 2011.
Permanent link
 

Description of Itmat Expertise

I am a physician scientist with a translational research focus in immunotherapy and cellular therapy. My research goals are to advance the understanding of immune responses mediated by cellular therapies, and to develop approaches that improve their efficacy and/or mitigate their toxicity. In particular, I am interested in how genetic variability affects immune responses and explains the heterogeneity in outcomes of cellular therapies and other immunotherapies. My chief hypothesis is that cellular therapies can be optimized by using personalized approaches that are based on understanding of the genetic heterogeneity of tumors, hosts and donors. In this context, my lab studies the role of lymphocyte trafficking receptors in anti-host and anti-tumor responses, which we have translated into a therapeutic intervention in humans using the CCR5 antagonist maraviroc.

Description of Research Expertise

I am a physician scientist with a translational research focus in immunotherapy and cellular therapy. My research goals are to advance the understanding of immune responses mediated by cellular therapies, and to develop approaches that improve their efficacy and/or mitigate their toxicity. In particular, I am interested in how genetic variability affects immune responses and explains the heterogeneity in outcomes of cellular therapies and other immunotherapies. My chief hypothesis is that cellular therapies can be optimized by using personalized approaches that are based on understanding of the genetic heterogeneity of tumors, hosts and donors. In this context, my lab studies the role of lymphocyte trafficking receptors in anti-host and anti-tumor responses, which we have translated into a therapeutic intervention in humans using the CCR5 antagonist maraviroc.

Selected Publications

Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL : High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol In Press, 2015.

Karimi M, Richman LP, Bryson JL, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T : Transient NKG2D Blockade Attenuates Graft-versus-Host Disease While Preserving Graft-versus-Tumor Effects. Blood In Press, 2015.

Luskin MR, Heil DS, Tan KS, Choi SM, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF, Tsai DE, Reshef R : The Impact of EBV Status on Characteristics and Outcomes of Post-Transplantation Lymphoproliferative Disorder Am J Transplant In Press, 2015.

Reshef R, Porter DL: Reduced-intensity conditioning for allogeneic stem-cell transplantation in adults with acute myeloid leukemia. Bone Marrow Transplant In Press, 2015.

Ganetsky A, Miano TA, Hughes ME, Vonderheide RH, Porter DL, Reshef R : Lack of a Significant Pharmacokinetic Interaction Between Maraviroc and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients. J Antimicrob chemother In Press, 2015.

Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL : Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant 20(11): 1758-66, November 2014.

Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL: Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367(2): 135-45, July 2012.

Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA, Tsai DE: Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder. Am J Transplant 11(2): 336-347, 2011.

Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, Porter DL, Heitjan DF, Tsai DE: Association of HLA Polymorphisms with Post-Transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. Am J Transplant 11(4): 817-825, 2011.

Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH: Functional unresponsiveness and replicative senescence of myeloid leukemia antigen- specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res 15: 4944-53, 2009.

back to top
Last updated: 03/15/2015
The Trustees of the University of Pennsylvania